Introduction {#s1}
============

Parkinson\'s disease (PD), the second most common neurodegenerative disease has an insidious onset and a long pre-symptomatic and symptomatic course. Four cardinal features that include resting tremor, bradykinesia, rigidity, and postural instability define the motor aspects of the disease. Different disease subtypes have been described including a tremor-predominant, akinetic/rigid predominant and mixed subtype ([@B1]). Non-motor features, including cognitive dysfunction, anosmia, anxiety, depression, sleep disorders, and autonomic dysfunction are also observed either alone or in varying combinations. Simuni et al. reported that for the Primary Progression Markers Initiative (PPMI) cohort, the higher baseline non-motor scores were associated with female sex and a more severe motor phenotype ([@B2]). Longitudinal increase in non-motor score severity was associated with older age and lower CSF aβ1--42 at baseline.

The temporal profile of the motor symptom appearance and progression is rather variable. A number of different patient cohorts have been followed longitudinally for different lengths of time and identified predictors of disease progression. Mollenhauer et al. analyzing the *De Novo* Parkinson (DeNOPA) cohort reported that baseline predictors of worse progression of motor symptoms included male sex, orthostatic blood pressure drop, diagnosis of coronary artery disease, arterial hypertension, elevated serum uric acid, and CSF neurofilament light chain ([@B3]). In the DeNOPA cohort, predictors of cognitive decline in PD were previous heavy alcohol abuse, current diagnoses of diabetes mellitus, arterial hypertension, elevated periodic limb movement index during sleep, decreased hippocampal volume by MRI, higher baseline levels of uric acid, C-reactive protein, high density lipoprotein (HDL) cholesterol, and glucose levels. In their cohort, risk markers for faster disease progression included cardiovascular risk factors, deregulated blood glucose, uric acid metabolism, and inflammation. Lawton et al. reported four clusters from the Tracking Parkinson\'s and Discovery cohorts: one with fast motor progression and symmetrical motor disease, poor olfaction, cognition, and postural hypotension; a second with mild motor and non-motor disease and intermediate motor progression; a third with severe motor disease, poor psychological well-being, and poor sleep with an intermediate motor progression; and a fourth with slow motor progression with tremor-dominant, unilateral disease ([@B4]). From the PPMI cohort, Aleksovski et al. reported that the postural instability gait disorder (PIGD) subtype was characterized by more severe disease manifestations at diagnosis, greater cognitive progression, and more frequent psychosis than tremor predominant patients ([@B5]). From the PPMI cohort, Latourelle et al. identified higher baseline MDS-UPDRS motor score, male sex, and increased age, as well as a novel Parkinson\'s disease-specific epistatic interaction, as indicative of faster motor progression ([@B6]). De Pablo-Fernandez et al. reported that the presence of autonomic symptoms contributed to a more rapid and severe disease course ([@B7]).

Comparing the findings of the different reported cohorts indicates partially overlapping clinical predictors. At the same time though, they reveal a variable clinical assessment. Here, we present an analysis of disease trajectory by GBTM in two large PD patient cohorts from five different countries followed at a routine clinical practice setting using identical clinical measures ([@B8]). We find that over an interval of 13 years, there are two trajectories, one with a more benign and another with a more severe disease progression. Patients can be reliably assigned to either group relatively early in their disease course.

Methods {#s2}
=======

Clinical Information
--------------------

Two patient cohorts with PD were included in the study: (1) the DNA Predictions to Improve Neurological Health (DodoNA) cohort, which includes patients that are followed longitudinally in the Department of Neurology at NorthShore University HealthSystem in Evanston, Illinois and (2) the Longitudinal Clinical and Genetic Study of Parkinson\'s Disease (LONG-PD) cohort that includes PD patients enrolled by clinician investigators from Norway, Greece, South Korea, and Sweden. These investigators entered their clinical data through REDCap, a web-based database. The patient information that was submitted from the four different sites is referred to as the LONG-PD cohort in aggregate. The cohorts included both previously diagnosed and naïve patients. A copy of the study protocol is available in the [Supplemental Information](#SM1){ref-type="supplementary-material"}.

The DodoNA Cohort
-----------------

The goal of interpreting variation in DNA to predict neurological disease led to naming the NorthShore cohort as the "DodoNA" cohort after the Dodona oracle of ancient Greece. The content of the electronic medical record-based (EPIC systems) SCDS toolkit was developed through frequent movement disorder neurologist meetings aimed to reach a consensus on the essential data elements that conform to Best Practices in the treatment of PD, parkinsonism, or tremor patients, taking into consideration relevant literature and American Academy of Neurology (AAN) guidelines ([@B9]), and the International Consortium for Health Outcomes Measurement (ICHOM) guidelines ([@B10]). The criteria for which rating scales and score test measures to include in the toolkit were: (a) to obtain clinically relevant information in a standardized manner that can be performed at regular intervals; and (b) that the standardized assessment can be performed during an office visit within the time limitations that are imposed by a routine office visit. The toolkit content consists of discretized fields that record detailed information regarding initial and current symptoms, medication history and treatment response, and imaging results, as well as score test measures, including the Geriatric Depression Scale (GDS) ([@B11]), Epworth Sleepiness Scale (ESS) ([@B12]), United Parkinson\'s Disease Rating Scale (UPDRS) ([@B13]), Part I---Mentation, Behavior and Mood, UPDRS Part II---Activities of Daily Living (ADLs), UPDRS-Part III---Motor Score, UPDRS-IV---Complications of Therapy (COT), UPDRS-Part V---Hoehn and Yahr staging (H&Y), UPDRS-Part VI---Schwab & England Score (S&E), and the Short Test of Mental Status (STMS) ([@B14]) that are autoscored. For cognitive assessment, initially, the MoCA (Montreal Cognitive Assessment) ([@B15]) was used. However, due to licensing permissions, the STMS was subsequently used. Both scores (MoCA and STMS) can be converted to the Mini-Mental State Examination (MMSE) published nomograms ([@B16]) (unpublished data, with permission of Dr. Bradley Boeve, Mayo Clinic, Rochester, MN, USA), and therefore, all cognitive scores are recorded as the MMSE converted score.

The implementation of the toolkit has been cost effective, and the annual follow-up rates using the toolkit exceeded 85%.

The LONG-PD Cohort
------------------

The clinical information for the LONG-PD cohort was entered by the neurologists from the four participant sites in the REDCap web-based tool designed for the electronic capture and sharing of data (<http://project-redcap.org/>). NorthShore built a REDCap form mirroring the DodoNA SCDS toolkit. A working group refined the form and defined required fields for all sites. The finalized form was presented at the annual meeting of the Genetic Epidemiology of Parkinson\'s Disease (GEoPD) Consortium in Vancouver, Canada (2015). All of the teams (DodoNA project, LONG-PD) are members of GEoPD. The REDCap format was chosen because it provides an easily accessible Interface for collecting and validating data, as well as automated data export to statistical packages in a secure, de-identified manner (SPSS, SAS, Stata, R).

Data Treatment
--------------

Subjects were excluded that experienced onset of symptoms 10 years or more prior to their initial visit or that had less than two valid visits (at 1 year or greater intervals). Prior to assessment, subject scores were assumed to be unknown, and the study was limited to a 13-year period covering all patient visits in the cohort. Missing motor assessment scores were imputed as zero for calculation of patient tremor and bradykinesia sub-scores.

Statistical Analysis
--------------------

Group-based trajectory modeling (GBTM) was applied to identify latent subgroups within the patient cohorts, given their covariates and assessment scores over time ([@B17], [@B18]). Assessment scores were taken on an annual basis during initial and annual follow-up visits. GBTM assigns individuals to separate latent subgroups with posterior probabilities over time and regression parameters to define the trajectory of those subgroups. The DodoNA cohort data were used as the training set and the LONG-PD data as the test set. The test set data were entered into the DodoNA model, and the output was compared to the LONG-PD test set for validation. This approach is illustrated in [Figure 1](#F1){ref-type="fig"}.

![Group-based Trajectory Modeling flowchart.](fneur-11-00548-g0001){#F1}

Trajectories were calculated based on the year of the reported initial symptom when the patient is seen for the first time in the movement disorder clinic, thus extending the trajectory duration to a maximum of 13 years that included at least 5 years of follow-up for the DodoNA cohort and 3 years of annual follow-up for the LONG-PD cohort. This choice to include the interval from the reported initial motor symptom allows a more accurate assessment of the disease course as often the patients come to the clinic at different points in the disease process.

We tested models with one to two subgroups using either constant or linear terms. The best-fitting results were selected using the lowest Bayesian information criterion (BIC) value. We used fixed covariates including patient gender, age of onset of symptoms, positive family history of PD with multiple-member instances, tremor predominance, presence of autonomic symptoms (orthostatism, urinary incontinence, constipation) individually and in combination, levodopa therapy, dopaminergic therapy, and years of education. Each of the fixed covariates was then measured across assigned subgroups to determine group membership totals and statistical significance across subgroups (Wilcoxon rank sum test for continuous variables: age of onset, years of education; Pearson\'s chi-squared test for count data: all other covariates).

Latent subgroup classes in GBTM cannot be externally validated. However, we attempted to validate whether GBTMs trained on the DodoNA cohort would be predictive of patient subgroup membership in the LONG-PD cohort. To do this, we trained GBTMs on the DodoNA patient cohort (the "training" set), and using their covariate estimates with respect to baseline, predicted subgroup membership when applied to LONG-PD patients for each sub-score. As a validation measure, we separately applied GBTM to the LONG-PD cohort using the same external model parameters (number of subgroups to stratify patients, shape of subgroup trajectories) and assumed these results to be the ground truth "test" set. We validated the overall results of the prediction and test sets using confusion matrices and statistics to assess the GBTM predictive value. The GBTM analysis was also performed in reverse with the LONG PD cohort as the training set and the DoDoNA cohort as the test set.

All data were analyzed using STATA/IC 16.0 using the PROC TRAJ package, and the significance level was set at 0.05.

Results {#s3}
=======

Statistical Analysis
--------------------

### Assignment of Patients to Different Disease Trajectories Based on Individual Clinical Scores

Individual clinical parameters were assessed for their effect on disease trajectory: With each clinical score with the exception of the tremor sub-score, two separate trajectories are clearly identified: one with a slower and less severe and one with a more rapid and more severe trajectory: for the H&Y stage (UPDRS-V) the group with a slower progression includes 73.2% of the cohort ([Figure 2A](#F2){ref-type="fig"}). This is also observed in the LONG-PD cohort ([Figure 2B](#F2){ref-type="fig"}) for 75.8% of the cohort. The validation for the LONG-PD prediction trained on the DodoNA test set is shown in [Figure 2C](#F2){ref-type="fig"} with a sensitivity of 0.9777 and a specificity of 0.7922.

![Hoehn and Yahr (H&Y) stage groups in the DNA Predictions to Improve Neurological Health (DodoNA) and Longitudinal Clinical and Genetic Study of Parkinson\'s Disease (LONG-PD) cohorts. **(A)** The model trained on DodoNA data (training set). **(B)** The model trained on the LONG-PD data (test set). **(C)** The validation for the LONG-PD prediction trained on NS data against the test set.](fneur-11-00548-g0002){#F2}

For the MMSE scores, a similar separation is seen with the larger subset \[83.8% in the DodoNA cohort ([Figure 3A](#F3){ref-type="fig"}) and 89.8% in the LONG-PD cohort ([Figure 3B](#F3){ref-type="fig"})\] having a slower progression. The validation for the LONG-PD prediction trained on the DodoNA test set is shown in [Figure 3C](#F3){ref-type="fig"} with a lower sensitivity of 0.54286 and a specificity of 0.99678. The apparent improvement of the MMSE scores, [Figure 3B](#F3){ref-type="fig"} probably reflects the smaller sample size of the LONG-PD cohort.

![Mini-Mental State Examination (MMSE) score groups in the DodoNA and LONG-PD cohorts. **(A)** The model trained on DodoNA data (training set). **(B)** The model trained on the LONG-PD data (test set). **(C)** The validation for the LONG-PD prediction trained on NS data against the test set.](fneur-11-00548-g0003){#F3}

For the UPDRS-III score, two groups are identified, with the slower progression group including 62% of the DodoNA cohort ([Figure 4A](#F4){ref-type="fig"}) and 57.2% of the LONG-PD cohort ([Figure 4B](#F4){ref-type="fig"}). The separation of the two trajectories appears less clear in the LONG-PD cohort, possibly reflecting treatment effects and shorter duration of follow-up. The validation for the LONG-PD prediction trained on the DodoNA test set is shown in [Figure 4C](#F4){ref-type="fig"} with a sensitivity of 0.8366 and a specificity of 0.9444.

![Motor Score groups in the DodoNA and LONG-PD cohorts. **(A)** The model trained on DodoNA data (training set). **(B)** The model trained on the LONG-PD data (test set). **(C)** The validation for the LONG-PD prediction trained on NS data against the test set.](fneur-11-00548-g0004){#F4}

For the tremor sub-score of UPDRS-III, two groups are again identified: the slower progression group of the DodoNA cohort including 47.2% ([Figure 5A](#F5){ref-type="fig"}) and the LONG-PD cohort 51% ([Figure 5B](#F5){ref-type="fig"}). The validation for the LONG-PD prediction trained on the DodoNA test set is shown in [Figure 5C](#F5){ref-type="fig"} with a sensitivity of 0.7857 and a specificity of 0.4479. The lower specificity that likely reflects the presence of tremor may not accurately reflect disease severity as it may be more sensitive to treatment effects.

![Unified Parkinson\'s Disease Rating Scale (UPDRS) (UPDRS)-III Tremor sub-score groups in the DodoNA and LONG-PD cohorts. **(A)** The model trained on DodoNA data (training set). **(B)** The model trained on the LONG-PD data (test set). **(C)** The validation for the LONG-PD prediction trained on NS data against the test set.](fneur-11-00548-g0005){#F5}

For the bradykinesia sub-score of UPDRS-III, two groups are again identified: the slower progression group of DodoNA cohort including 62.7% ([Figure 6A](#F6){ref-type="fig"}) and the LONG-PD cohort including 24.7% ([Figure 6B](#F6){ref-type="fig"}). The validation for the LONG-PD prediction trained on the DodoNA test set is shown in [Figure 6C](#F6){ref-type="fig"} with a sensitivity of 1.000 and a specificity of 0.4648. The lower specificity likely indicated that sub-scores may not accurately reflect disease severity, as they only represent separate cardinal features and do not assess rigidity and postural instability.

![UPDRS-III Bradykinesia sub-score in the DodoNA and LONG-PD cohorts. **(A)** The model trained on DodoNA data (training set). **(B)** The model trained on the LONG-PD data (test set). **(C)** The validation for the LONG-PD prediction trained on NS data against the test set.](fneur-11-00548-g0006){#F6}

The UPDRS-II ADL score separates patients in two different trajectories, with 66.2% of the DodoNA cohort ([Figure 7A](#F7){ref-type="fig"}) and 78.9% of the LONG-PD cohort ([Figure 7B](#F7){ref-type="fig"}) showing a slow trajectory. The validation for the LONG-PD prediction trained on the DodoNA test set is shown in [Figure 7C](#F7){ref-type="fig"} with a sensitivity of 0.9892 and a specificity of 0.7313. It is important to note that the UPDRS-II score reflects historical information and subject to a subjective assessment.

![Activities of Daily Living (ADL) scores in the DodoNA **(A)** and LONG-PD **(B)** cohorts. **(C)** The validation for the LONG-PD prediction trained on NS data against the test set.](fneur-11-00548-g0007){#F7}

To determine adherence to a particular group identified in the GBTM, convergence graphs were generated based on the assumption that the group assignment at year 13 is the "true group." In addition, convergence graphs provide information regarding the time point in the disease course where patients can be reliably classified to their "true group." The time point in which the two trajectories appear to be horizontal reflects the time point when the group assignments "converge" to their "true groups." For H&Y stage for both the DodoNA and LONG-PD cohorts, year 9 represents the time point in which group assignment more closely reflects the "true group" assignment ([Figures 8B](#F8){ref-type="fig"}, [9B](#F9){ref-type="fig"}). For the MMSE score in the DodoNA cohort, this time point is delayed at year 10 ([Figure 8A](#F8){ref-type="fig"}), whereas in the LONG-PD cohort, it occurs earlier in year 8 ([Figure 9A](#F9){ref-type="fig"}). For UPDRS-III and II, that time point is later ([Figures 8C,D](#F8){ref-type="fig"}, [9C,D](#F9){ref-type="fig"}). Taken together, these results point to the H&Y stage and the MMSE as reliable predictors of trajectory group assignment and identify a point relatively early in the disease trajectory in which group assignment can be made.

![Convergence scores for MMSE **(A)**, H&Y stage **(B)**, UPDRS-III **(C)**, and UPDRS-II **(D)** for the DodoNA cohort.](fneur-11-00548-g0008){#F8}

![Convergence scores for MMSE **(A)**, H&Y stage **(B)**, UPDRS-III **(C)**, and UPDRS-II **(D)** for the LONG-PD cohort.](fneur-11-00548-g0009){#F9}

To further investigate the possibility of the misclassification rate for group assignments, misclassification graphs were generated assuming that the assignment at year 13 is the "true group," complementing the convergence analysis. In the case of H&Y trajectory, convergence was at year 9. At year 9, the misclassification (i.e., 1-accuracy) is 0.05, representing a 5% error rate for group 2 and almost 0% error for group 1 assignment. Based on these graphs, the H&Y stage provides an "acceptable error rate" in both cohorts ([Figures 10](#F10){ref-type="fig"}, [11](#F11){ref-type="fig"}).

![Misclassification scores for MMSE **(A)**, H&Y stage **(B)**, UPDRS-III **(C)**, and UPDRS-II **(D)** for the DodoNA cohort.](fneur-11-00548-g0010){#F10}

![Misclassification scores for MMSE **(A)**, H&Y stage **(B)**, UPDRS-III **(C)**, and UPDRS-II **(D)** for the LONG-PD cohort.](fneur-11-00548-g0011){#F11}

To ascertain the reliability of the analyses, the LONG-PD cohort was used as a training set and the DodoNA cohort as the test set. Both types of analyses provided similar results (data not shown).

### Covariates Contributing to Trajectory Group Assignment

From the covariates entered into the model, the following contribute to group assignment: older AAO for both cohorts and male sex only for the DodoNA cohort assign patients to the more severe group (group 2) and tremor-predominant disease subtype to the benign group (group 1). Interestingly for tremor scores in the DodoNA cohort only, years of education assigns patients to group 1. Bradykinesia and AAO in the DodoNA cohort only assign patients to group 2. The tremor-predominant subtype in the LONG-PD, but not the DodoNA cohort, assigns patients to group 1. Interestingly, levodopa and dopaminergic therapy are not significant for the DodoNA cohort but are significant for the LONG-PD cohort. Complications of therapy do not contribute to group assignment (data not shown). Cognitive impairment at disease onset likely assigns patients to group 2. The differences noted between the two cohorts may reflect different sample sizes or genetic background effects. Group counts are shown in [Table 1](#T1){ref-type="table"} and the effect of covariates in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. To assess whether the presence of autonomic symptoms contributes to a more rapid and severe course in PD, we also assessed both cohorts for the presence of autonomic symptoms. Orthostatism, urinary incontinence, and constipation were the most prevalent autonomic symptoms. Therefore, we included these in the analysis, individually and in combination. They did not contribute, either individually or in combination, to a more severe disease course in our cohorts.

###### 

Group counts from the DNA Predictions to Improve Neurological Health (DodoNA) and Longitudinal Clinical and Genetic Study of Parkinson\'s Disease (LONG-PD) cohorts.

  **DodoNA cohort**                                       **Group 1**    **Group 2**
  ------------------------------------------------------- -------------- --------------
  Hoehn and Yahr (H&Y) stage                              291 (73.48%)   105 (26.52%)
  Mini Mental State Examination (MMSE)                    59 (14.9%)     337 (85.1%)
  Unified Parkinson\'s Disease Rating Scale (UPDRS)-III   251 (63.38%)   145 (36.62%)
  UPDRS-II                                                266 (67.17%)   130 (32.83%)
  Tremor sub-score                                        188 (47.47%)   208 (52.53%)
  Bradykinesia sub-score                                  247 (63.01%)   145 (36.99%)
  **LONG-PD cohort**                                      **Group 1**    **Group 2**
  H&Y                                                     269 (77.75%)   77 (22.25%)
  MMSE                                                    35 (10.12%)    311 (89.88%)
  UPDRS-III                                               203 (58.67%)   143 (41.33%)
  UPDRS-II                                                279 (80.64%)   67 (19.36%)
  Tremor sub-score                                        182 (52.6%)    164 (47.4%)
  Bradykinesia sub-score                                  86 (24.86%)    260 (75.14%)

###### 

Summary statistics, DodoNA cohort: AAO and YOE are continuous covariates and their group values represent within-group means.

  **H&Y stage**                           **Group 1**   **Group 2**   ***P*-value**
  --------------------------------------- ------------- ------------- ---------------
  AAO[^a^](#TN1){ref-type="table-fn"}     66.0          75.0          \<0.0001
  YOE[^b^](#TN2){ref-type="table-fn"}     16.0          16.0          \<0.0001
  FH\>1[^c^](#TN3){ref-type="table-fn"}   12            5             0.7817
  FH                                      69            22            0.6594
  TDS                                     71            4             \<0.0001
  LD[^d^](#TN4){ref-type="table-fn"}      254           90            0.8103
  DP[^e^](#TN5){ref-type="table-fn"}      94            23            0.0605
  Male sex                                221           64            0.0050
  **MMSE**                                                            
  AAO                                     75.0          67.0          \<0.0001
  YOE                                     15.0          16.0          \<0.0001
  FH\>1                                   2             15            1.0000
  FH                                      11            80            0.4899
  TPS[^f^](#TN6){ref-type="table-fn"}     8             67            0.3354
  LD                                      52            292           0.9176
  DP                                      9             108           0.0141
  Male sex                                48            237           0.1134
  **UPDRS-III (Motor)**                                               
  AAO                                     67.0          72.0          \<0.0001
  YOE                                     16.0          16.0          \<0.0001
  FH\>1                                   11            6             1.0000
  FH                                      59            32            0.8388
  TPS                                     60            15            0.0014
  LD                                      212           132           0.0871
  DP                                      80            37            0.2221
  Male sex                                171           114           0.0337
  **UPDRS-II (ADL)**                                                  
  AAO                                     68.0          70.0          \<0.0001
  YOE                                     16.0          16.0          \<0.0001
  FH\>1                                   12            5             0.9660
  FH                                      63            28            0.7268
  TPS                                     59            16            0.0266
  LD                                      231           113           1.0000
  DP                                      83            34            0.3592
  Male sex                                188           97            0.4837
  **UPDRS-III Tremor sub-score**                                      
  AAO                                     69.0000       68.0000       \<0.0001
  YOE                                     16.0000       16.0000       \<0.0001
  FH\>1                                   8             9             1.0000
  FH                                      51            40            0.0809
  TDS                                     0             75            \<0.0001
  LD                                      171           173           0.0322
  DP                                      60            57            0.3831
  Male sex                                130           155           0.2819
  **UPDRS-III bradykinesia sub-score**                                
  AAO                                     65.0          74.0          \<0.0001
  YOE                                     16.0          16.0          \<0.0001
  FH\>1                                   9             8             0.5569
  FH                                      60            31            0.5354
  TPS                                     67            8             \<0.0001
  LD                                      211           133           0.2263
  DP                                      81            36            0.0999
  Male sex                                177           108           0.8198

*Other covariates are binary, and as such, their values represent within-group sums of positive membership. P-values display statistical significance across groups*.

*AAO, age at onset*;

*YOE, years of education*;

*FH, family history*;

*LD, levodopa therapy*;

*DP, dopaminergic therapy*;

*TPS, tremor-predominant subtype*.

###### 

Summary statistics from the LONG-PD cohort: AAO and YOE are continuous variables and their group values represent within-group means.

                                         **Group 1**   **Group 2**   ***P*-value**
  -------------------------------------- ------------- ------------- ---------------
  **H&Y stage**                                                      
  AAO                                    61.0          67.0          \<0.0001
  YOE                                    12.0          10.0          \<0.0001
  FH\>1                                  26            6             0.7816
  FH                                     29            11            0.5183
  TPS                                    75            4             \<0.0001
  LD                                     248           61            0.0024
  DP                                     142           39            0.8400
  Male sex                               139           36            0.5273
  **MMSE**                                                           
  AAO                                    69.0          62.0          \<0.0001
  YOE                                    6.0           12.0          \<0.0001
  FH \>1                                 1             31            0.2269
  FH                                     2             38            0.4014
  TPS                                    8             71            1.0000
  LD                                     24            285           0.0003
  DP                                     13            168           0.0860
  Male sex                               16            159           0.6681
  **UPDRS-III (Motor)**                                              
  AAO                                    59.0          67.0          \<0.0001
  YOE                                    12.0          10.0          \<0.0001
  FH\>1                                  18            14            0.9176
  FH                                     23            17            1.0000
  TPS                                    56            23            0.0173
  LD                                     186           123           0.1371
  DP                                     115           66            0.0694
  Male sex                               105           70            1.0000
  **UPDRS-II (ADL)**                                                 
  AAO                                    61.0          67.0          \<0.0001
  YOE                                    11.0          10.0          \<0.0001
  FH\>1                                  26            6             1.0000
  FH                                     32            8             1.0000
  TPS                                    67            12            0.3645
  LD                                     264           45            \<0.0001
  DP                                     150           31            0.3337
  Male sex                               135           40            0.1267
  **UPDRS-III tremor sub-score**                                     
  AAO                                    62.0          63.0          1.0000
  YOE                                    12.0          11.0          1.0000
  FH\>1                                  21            11            0.1729
  FH                                     26            14            0.1332
  TPS                                    39            40            0.5981
  LD                                     152           157           0.0005
  DP                                     80            101           0.0015
  Male sex                               101           74            0.0689
  **UPDRS-III bradykinesia sub-score**                               
  AAO                                    62.0000       62.0000       1.0000
  YOE                                    10.0000       12.0000       \<0.0001
  FH\>1                                  9             23            0.8146
  FH                                     12            28            0.5445
  TPS                                    31            48            0.0013
  LD                                     60            249           \<0.0001
  DP                                     30            151           0.0003
  Male sex                               46            129           0.6183

*Other variables are binary, and as such, their values represent within-group sums of positive membership. P-values display statistical significance across groups*.

Genotypes were assessed for the presence of *LRRK2* and *GBA* mutations. The prevalence of *LRRK2* and *GBA* pathogenic variants was 1.89%and 2.96%, respectively. The vast majority of these were in the DodoNA, a United States-based cohort. In combination with the lack of significant contribution of family history to the disease trajectory, this suggests that in these two cohorts, at least some genetic factors do not contribute to the disease trajectory.

Discussion {#s4}
==========

Longitudinal monitoring of PD over long time intervals is essential in order to obtain a more accurate characterization of patterns in the disease course and clinical outcomes, as well as to gain insights into disease etiology. Here, we present a group-based trajectory modeling analysis of five ethnically different PD patient cohorts from the United States (the DodoNA cohort) and from Norway, South Korea, Greece, and Sweden (the LONG-PD cohort) within the GEoPD consortium (<https://geopd.lcsb.uni.lu/>). The trajectory analysis is based on standardized clinical assessment that takes place at annual intervals in the routine office setting. The choice of clinical assessment parameters reflects a consensus among clinicians with different backgrounds and practice modes and which would facilitate data collection and entry using a web-based format. The analysis of a maximum of 13-year disease course identifies two distinct groups: a slower and more benign course and a faster, more malignant course. Clinical predictors of group assignment include male sex, age at disease onset, presence of tremor as a predominant clinical feature, years of education, and cognitive impairment at onset. Interestingly, levodopa/dopaminergic therapy and family history do not contribute to group assignment. The significance of beneficial effect of years of education for assignment to a particular disease trajectory is supported by the findings of Lee et al., which implicate a passive reserve hypothesis for motor/non-motor symptoms of PD ([@B19]). The somewhat unexpected lack of contribution of family history in group assignment may reflect the diverse genetic background of the two cohorts.

Adherence to a particular group occurs at mid-stage disease and remains stable thereafter for the study interval. Interestingly, complications of therapy do not appear to contribute to the assignment to individual trajectories. It is interesting to point out that while there is significant overlap between cohorts for the different covariates, there are covariates in which the two cohorts diverge. This may be explained by the different cohort sizes, but it may also reflect different genetic, environmental, and cultural factors. The prevalence of *LRRK2* disease causing variants in sporadic PD has been reported between 0.5 and 2% ([@B20], [@B21]) and that of *GBA* between 2.3 and 9.4% ([@B22]) in the U.S. population, similar to what we find in our cohort. It seems unlikely that the low percentage of *LRRK2* and *GBA* disease-causing variants drives trajectory classification as there is a lack of contribution of family history to trajectory classification. This suggests that genetic factors are not likely to have at best a modest effect.

The GBTM analysis presented here has several strengths: (a) it employs easily assessed standardized clinical parameters that can be assessed at annual intervals and identifies predictable patterns of disease progression; (b) the analysis is performed over a long disease duration (maximum of 13 years); (c) it identifies individual clinical predictors of trajectory patterns; (d) the accurate clinical phenotypic characterization provides an essential background for genotype--phenotype correlations, currently ongoing in our study; (e) it provides an informative template for large-scale clinical and genomic studies.

Our study has also some limitations. Since the intent of this study was to assess measures that could be evaluated in a routine clinical setting, a limitation is its assessment of a narrower spectrum of phenotypic characteristics than other comprehensively studied cohorts such as the PPMI, DeNOPA, and LABS-PD cohorts ([@B2]--[@B6], [@B23]). Specifically, in our cohorts, CSF analyses, SPECT scans, quantitative olfactory assessment, and polysomnograms were not obtained routinely. Since the study protocols of other longitudinally studied cohorts vary in aims and scope, direct comparisons with our study are challenging. These issues would be better addressed by a meta-analysis.

A second limitation of our study is the lack of autopsy data. However, over a quarter of participants underwent SPECT scans that were abnormal. In the absence of autopsy data, an abnormal SPECT scan in the context of clinically definite PD (Bower criteria) confirms the clinical diagnosis. In that context, it should also be pointed out that the diagnosis of PD in our study was assessed and confirmed at each annual interval.

A strength of this study is that detailed information on comorbidities, head injury, complications of dopaminergic therapy, autonomic dysfunction (orthostatic symptoms, anhidrosis/hyperhidrosis, urinary incontinence), sleep disorders, dysphagia, anxiety, and depression have been, and continue to be, collected at annual intervals. As the study is ongoing, these will continue to be analyzed to inform conclusions regarding the spectrum of factors that contribute to the disease course in intervals longer than 5 years. It is important to point out that the focus of the analysis presented here is to identify individual, clinical parameters that reflect the cardinal features of the disease as well as assess the effect of other covariates on those parameters. Furthermore, it is important to stress that the clinical data collected in the DodoNA and LONG-PD cohorts are pragmatic and can be easily collected within routine clinical practice settings worldwide. Identifying what features in this simplified, reproducible set of clinical parameters can predict disease course complements findings from other longitudinally followed disease cohorts.

In conclusion, the longitudinal study of the DodoNA and the LONG-PD cohorts combines clinically meaningful, easily obtainable information from ethnically different PD cohorts and demonstrates that clinical parameters assessed in the routine office setting can help predict clinical outcomes in PD as well as inform our understanding of the underlying neurodegenerative process. Large international consortia to understand genetic risk factors contributing to PD have been formed where phenotypic information is sketchy and often minimal. This work demonstrates that a detailed phenotypic characterization is essential in informing and interpreting the data from such consortia. The development of the LONG-PD protocol has led to the adoption of a somewhat simplified version of phenotypic information collection by a majority of the GEoPD participating sites and can be easily adapted for genomic information obtained by other international consortia. Ongoing genotype--phenotype analyses will identify molecular predictors of the disease trajectories. Longer longitudinal follow-up of \>10 years will help determine whether the adherence to the identified trajectories remains stable or whether splintering occurs as the disease process advances.
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